Storage Instructions Storage requirements should match the exact GHK-Cu preparation
Strict ingredient separation prevents cumulative irritation
Esposito G, Dottori L, Pivetta G, et al
Temperature reference table This table represents general guidelines
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
While many people can safely get these shots, those with certain health conditions should talk to their doctor first